Five Pharma Approvals from 2023
In some of the most notable pharmaceutical approvals from 2023, drugs for RSV, CF, COVID-19, sickle cell disease, and opioid overdose received an FDA stamp in 2023.
In some of the most notable pharmaceutical approvals from 2023, drugs for RSV, CF, COVID-19, sickle cell disease, and opioid overdose received an FDA stamp in 2023.
Vertex Pharmaceuticals data presented at the 41st European Cystic Fibrosis Conference supports the potential disease-modifying benefits of treating the underlying cause of CF.
Over 3,100 people in North America, Europe and Australia with the CF R117H mutation will have a new treatment option with the new Kalydeco approval.
The company announced plans to begin clinical trials of the potential cystic fibrosis therapy Kalydeco (VX-770) in more patient groups–including children as young as 2 years old–later this year.
Read More